Want to see BPTH full AI Analyst Report?
Bio-Path Holdings (BPTH) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bp1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (In Combination With Bp1002) | Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, In Relapse | Phase I | Recruiting | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | Dec 08, 2021 | ― |
| Bp1001-A (Liposomal Grb2 Antisense Oligonucleotide), Bp1001-A (Liposomal Grb2 Antisense Oligonucleotide) With Paclitaxel | Solid Tumor, Solid Tumor, Adult, Endometrial Cancer, Peritoneal Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms | Phase I | Recruiting | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Dec 10, 2019 | ― |
| L-Bcl-2 Antisense Oligonucleotide | Follicular Lymphoma, Marginal Zone Lymphoma, Dlbcl, Mantle Cell Lymphoma, Waldenstrom Macroglobulinemia, Hodgkin Lymphoma, Small Lymphocytic Lymphoma (Sll), Chronic Lymphocytic Leukemia (Cll), Peripheral T-Cell Lymphoma (Ptcl), Cutaneous T-Cell Lymphoma (Ctcl) | Phase I | Active Not Recruiting | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Aug 23, 2019 | ― |
| Bp1001 In Combination With Ventoclax Plus Decitabine, Bp1001 Plus Decitabine | Acute Myeloid Leukemia (Aml) | Phase II | Recruiting | Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | May 18, 2016 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bp1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (In Combination With Bp1002) | Phase I | Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, In Relapse | Recruiting | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | Dec 08, 2021 | ― |
| Bp1001-A (Liposomal Grb2 Antisense Oligonucleotide), Bp1001-A (Liposomal Grb2 Antisense Oligonucleotide) With Paclitaxel | Phase I | Solid Tumor, Solid Tumor, Adult, Endometrial Cancer, Peritoneal Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms | Recruiting | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Dec 10, 2019 | ― |
| L-Bcl-2 Antisense Oligonucleotide | Phase I | Follicular Lymphoma, Marginal Zone Lymphoma, Dlbcl, Mantle Cell Lymphoma, Waldenstrom Macroglobulinemia, Hodgkin Lymphoma, Small Lymphocytic Lymphoma (Sll), Chronic Lymphocytic Leukemia (Cll), Peripheral T-Cell Lymphoma (Ptcl), Cutaneous T-Cell Lymphoma (Ctcl) | Active Not Recruiting | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Aug 23, 2019 | ― |
| Bp1001 In Combination With Ventoclax Plus Decitabine, Bp1001 Plus Decitabine | Phase II | Acute Myeloid Leukemia (Aml) | Recruiting | Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | May 18, 2016 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Bio-Path Holdings (BPTH) have in its pipeline
Bio-Path Holdings BPTH is currently developing the following drugs: Bp1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (In Combination With Bp1002), Bp1001-A (Liposomal Grb2 Antisense Oligonucleotide), Bp1001-A (Liposomal Grb2 Antisense Oligonucleotide) With Paclitaxel, L-Bcl-2 Antisense Oligonucleotide, Bp1001 In Combination With Ventoclax Plus Decitabine, Bp1001 Plus Decitabine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
